Halozyme Therapeutics (HALO) Asset Utilization Ratio (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Asset Utilization Ratio data on file, last reported at 0.58 in Q1 2026.

• On a quarterly basis, Asset Utilization Ratio rose 14.01% year-over-year to 0.58 in Q1 2026; TTM through Mar 2026 was 0.58, a 14.01% increase from a year earlier, with the FY2025 full-year figure at 0.61, up 13.81% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.58, down from 0.59 in the prior quarter.
• Over the last five years, Asset Utilization Ratio for HALO reached as high as 0.59 in Q4 2025 and fell as low as 0.32 in Q3 2022.
• Historically, Asset Utilization Ratio has averaged 0.46 across 5 years, with a median of 0.46 in 2024.
• Across the five-year window, Asset Utilization Ratio declined 23.94% in 2022 and surged 33.1% in 2023, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.36 in 2022, then gained by 28.4% to 0.46 in 2023, then increased by 6.17% to 0.49 in 2024, then grew by 21.18% to 0.59 in 2025, then decreased by 1.37% to 0.58 in 2026.
• Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.58 in Q1 2026, 0.59 in Q4 2025, and 0.58 in Q3 2025.